X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/chiesi-offers-affibody-breath-fresh-air-new-respiratory-disease-deal-worth-637m-biobucks
https://www.prnewswire.com/news-releases/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-data-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-presented-during-2022-european-alliance-of-associations-for-rheumatology-congress-301560613.html
https://www.prnewswire.com/news-releases/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-positive-interim-results-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-301443555.html
https://www.fiercebiotech.com/biotech/acelyrin-reels-250m-to-fund-three-late-stage-trials-inflammatory-disease-antibody-licensed
https://www.mynewsdesk.com/se/affibody/pressreleases/affibody-and-inmagene-announce-first-patient-dosed-in-the-global-phase-2-aspire-trial-of-izokibep-for-patients-with-active-ankylosing-spondylitis-3123231
https://www.mynewsdesk.com/se/affibody/pressreleases/affibody-announces-initiation-of-confirmatory-phase-2-trial-of-aby-035-in-psoriatic-arthritis-patients-3049819
https://www.affibody.se/affibody-announces-positive-top-line-data-from-phase-2-proof-of-concept-trial-of-aby-035-in-psoriasis/
Market Place
Share 
